Are you Dr. Peacock?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 68 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
2004 Hayes St
Ste 350
Nashville, TN 37203Phone+1 615-312-3333Fax+1 615-320-7091
Summary
- Dr. Nancy Peacock, MD is an oncologist in Nashville, Tennessee. She is currently licensed to practice medicine in Tennessee and Texas. She is affiliated with Ascension Saint Thomas, TriStar Centennial Medical Center, and TriStar NorthCrest Medical Center.
Education & Training
University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineFellowship, Hematology and Medical Oncology, 1991 - 1993- University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineResidency, Internal Medicine, 1988 - 1991
University of Missouri-Columbia School of MedicineClass of 1988
Certifications & Licensure
TN State Medical License 1995 - 2026
TX State Medical License 1989 - 1996- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Retrospective Cohort Study of Infusion Reactions Due to Vectibix Start of enrollment: 2010 Jun 01
Publications & Presentations
PubMed
- 6 citationsA Phase II Study Evaluating Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients With Androgen Receptor (AR)-Expressing Metastatic Breast Cancer (MBC).Denise A. Yardley, Robyn R. Young, Kerin B. Adelson, Andrea Silber, Jose E. Najera
Clinical Breast Cancer. 2021-10-28 - 5 citationsPhase II trial of eribulin in patients who do not achieve pathologic complete response (pCR) following neoadjuvant chemotherapyDenise A. Yardley, N. W. Peacock, Brooke R. Daniel, Betrand Anz, David C. Molthrop
Breast Cancer Research and Treatment. 2020-02-14 - 14 citationsA Phase II Study of the Combination of Bevacizumab, Pertuzumab, and Octreotide LAR for Patients with Advanced Neuroendocrine CancersJohanna C. Bendell, Ahmed Zakari, Evan Z. Lang, David M. Waterhouse, Douglas Flora
Cancer Investigation. 2016-04-29
Professional Memberships
- Member
